# Emalex Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emalex-biosciences

- Industry: Pharmaceuticals
- Headquarters: Chicago, US
- Website: www.emalexbiosciences.com
- Total disclosed funding: $285M
- Latest round: Series D (Nov 3, 2022)
- Investors on record: 4

## About

Emalex Biosciences, Inc. is a Chicago-based biotech company specializing in the development of innovative treatments for central nervous system disorders, particularly focusing on Tourette syndrome.Founded in 2018 in Chicago, US, Emalex Biosciences is dedicated to developing therapies for Tourette syndrome. The company raised USD 250.00 mn in Series D funding led by Bain Capital in November 2022. Eric Messner and Jeffrey Aronin currently serve as CEO. The company has engaged in two deals to date.Emalex Biosciences specializes in developing innovative treatments for central nervous system disorders, focusing on Tourette syndrome. The company is advancing ecopipam, a dopamine-1 (D1) receptor antagonist, to reduce tic severity in both pediatric and adult patients, addressing a significant unmet need in treatment options for TS.Emalex Biosciences generates revenue through partnerships and clinical trials related to ecopipam. The company is conducting late-stage studies to validate its drug's efficacy and safety, with revenue models involving B2B transactions with healthcare providers and potential licensing agreements for its proprietary formulations.In November 2022, Emalex raised USD 250.00 mn in Series D funding to manage clinical trials in North America for patients with Tourette syndrome. The company aims to expand its market presence and is focused on advancing ecopipam towards regulatory approval, with initiatives planned to enhance accessibility and distribution in the neurological therapeutic market.

## Funding rounds

- Series D, Nov 3, 2022, $250M — Bain Capital, Valor Equity Partners, Fidelity Investments, Paragon Biosciences LLC
- Series C, Mar 23, 2021, $35M — Valor Equity Partners, Fidelity Investments, Paragon Biosciences LLC

## Investors

- Valor Equity Partners (https://capitalatlas.ai/funds/valor-equity-partners) — Series C, Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C, Series D
- Paragon Biosciences LLC — Series C, Series D
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series D